167 related articles for article (PubMed ID: 21745166)
1. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
Hu X; Xu J; Sun A; Shen Y; He G; Guo F
Leuk Lymphoma; 2011 Dec; 52(12):2393-5. PubMed ID: 21745166
[No Abstract] [Full Text] [Related]
2. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577
[TBL] [Abstract][Full Text] [Related]
3. Cancer research. Taking garbage in, tossing cancer out?
Garber K
Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
[No Abstract] [Full Text] [Related]
4. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
Szczepanek J; Pogorzala M; Konatkowska B; Juraszewska E; Badowska W; Olejnik I; Kuzmicz M; Stanczak E; Malinowska I; Stefaniak J; Sobol G; Szczepanski T; Czyzewski K; Wysocki M; Styczynski J
Anticancer Res; 2010 Jun; 30(6):2119-24. PubMed ID: 20651360
[TBL] [Abstract][Full Text] [Related]
5. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
6. The proteasome--an emerging therapeutic target in cancer.
Mitchell BS
N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
[No Abstract] [Full Text] [Related]
7. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
Horton TM; Pati D; Plon SE; Thompson PA; Bomgaars LR; Adamson PC; Ingle AM; Wright J; Brockman AH; Paton M; Blaney SM
Clin Cancer Res; 2007 Mar; 13(5):1516-22. PubMed ID: 17332297
[TBL] [Abstract][Full Text] [Related]
8. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
9. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
10. The role of bortezomib in the treatment of lymphoma.
Barr P; Fisher R; Friedberg J
Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
[TBL] [Abstract][Full Text] [Related]
11. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Lesovaya E; Yemelyanov A; Kirsanov K; Popa A; Belitsky G; Yakubovskaya M; Gordon LI; Rosen ST; Budunova I
Cell Cycle; 2013 Jan; 12(1):133-44. PubMed ID: 23255118
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Gerecitano J; Portlock C; Moskowitz C; Hamlin P; Straus D; Zelenetz AD; Zhang Z; Dumitrescu O; Sarasohn D; Lin D; Pappanicholaou J; Cortelli BM; Neylon E; Hamelers R; Wright J; O'Connor OA
Br J Haematol; 2009 Sep; 146(6):652-5. PubMed ID: 19624539
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
Park JW; Qi WN; Cai Y; Urbaniak JR; Chen LE
Plast Reconstr Surg; 2007 Dec; 120(7):1808-1818. PubMed ID: 18090742
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological and clinical profile of Bortezomib (Velcade)].
Fujii H; Kotobuki Y; Nomura S; Harada Y
Nihon Yakurigaku Zasshi; 2007 Nov; 130(5):421-9. PubMed ID: 18000359
[No Abstract] [Full Text] [Related]
18. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
19. [Effects of proteasome inhibitors on leukemias].
Lü SQ; Yang JM; Wang JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):896-900. PubMed ID: 17708829
[TBL] [Abstract][Full Text] [Related]
20. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Kelley TW; Alkan S; Srkalovic G; Hsi ED
Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
